MiNK Therapeutics iNKT Data for IPF
Analysis based on 8 articles · First reported Feb 04, 2026 · Last updated Feb 04, 2026
The announcement by MiNK Therapeutics of positive translational data for iNKT cells in Idiopathic pulmonary fibrosis (IPF) is likely to positively impact MiNK Therapeutics' stock price and investor confidence. This development could also stimulate interest in the broader biotechnology sector focused on chronic fibrotic lung diseases, as it addresses a significant unmet medical need.
MiNK Therapeutics announced new translational data at the Keystone Symposia, demonstrating a significant depletion of invariant natural killer T (iNKT) cells in lung-associated lymph nodes from patients with end-stage Idiopathic pulmonary fibrosis (IPF). Dr. Terese Hammond, Head of Pulmonary and Inflammatory Diseases at MiNK Therapeutics, presented these findings, which support a mechanistic role for iNKT insufficiency in advanced IPF. This work provides direct human tissue evidence for iNKT insufficiency and strengthens the rationale for iNKT cell replenishment strategies as a potential approach to restoring immune balance and supporting tissue repair in fibrotic lung disease. The findings expand MiNK Therapeutics' platform relevance into chronic fibrotic and senescence-associated indications, complementing ongoing development programs for AgenT-797 in oncology, GVHD, and severe pulmonary inflammation. IPF is a fatal, progressive lung disease affecting approximately 100,000 patients in the United States, representing a substantial global unmet medical need.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard